COMPANY

Scioto Biosciences, Inc.

HQ: Indianapolis, IN source · sciotobiosciences.com ↗ · Midwest

Also known as Scioto Biosciences · 3 sources

Scioto is developing SB-121 for the treatment of patients with Autism and other GI disorders. From company website Source · Oct 12, 2026

Keywords: neurology autistic disorder

Location: Indianapolis, IN · source · Oct 14, 2026

Profile checked Oct 10, 2026

Timeline

Aug 2, 2021 Trial start Phase 1: 28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorde source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT04944901	28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder	Phase 1	Completed	Aug 2, 2021	Mar 3, 2022 (actual)

Annual award amounts. Total $2.3M.

Jul 29, 2020 NIH award 5R44GM122130-03 FY2020: $1,134,186 awarded for that fiscal year; activity R44 (SBIR); PI TREBLEY, JOE; recipient as written: SCIOTO BIOSCIENCES, INC., INDIANAPOLIS, IN. A Novel Probiotic Platform to Treat N source ↗
Aug 15, 2019 NIH award 2R44GM122130-02 FY2019: $1,150,153 awarded for that fiscal year; activity R44 (SBIR); PI TREBLEY, JOE; recipient as written: SCIOTO BIOSCIENCES, INC., INDIANAPOLIS, IN. A Novel Probiotic Platform to Treat N source ↗